Federal Register of Legislation - Australian Government

Primary content

PB 69 of 2022 Determinations/Health as made
This instrument amends the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 104 of 2019) to add, delete and alter listed pharmaceutical items for which a dangerous drug fee applies and add, delete and alter listed pharmaceutical items which must be supplied as a complete pack.
Administered by: Health and Aged Care
Registered 29 Jul 2022
Tabling HistoryDate
Tabled HR01-Aug-2022
Tabled Senate02-Aug-2022
To be repealed 23 Nov 2022
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003
Table of contents.

 

Commonwealth Coat of Arms of Australia

 

PB 69 of 2022

 

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 5)

 

National Health Act 1953

___________________________________________________________________________

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 98C(1) of the National Health Act 1953.

 

Dated                   28 July 2022

NIKOLAI TSYGANOV

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

 

 


Contents

1.......... Name............................................................................................................................................ 1

2.......... Commencement............................................................................................................................ 1

3.......... Authority...................................................................................................................................... 1

4.......... Schedules..................................................................................................................................... 1

Schedule 1—Amendments                                                                                                                          2

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019                                                                                                              

 

 

 

 


1     Name

(1)          This Instrument is the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 5).

(2)          This Instrument may also be cited as PB 69 of 2022.

2     Commencement

(1)          Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 August 2022

1 August 2022

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)          Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3     Authority

This instrument is made under subsection 98C(1) of the National Health Act 1953.

4     Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.


 

Schedule 1Amendments

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)

[1]        Schedule 3, entry for Hydromorphone

            omit: Oral solution containing hydromorphone hydrochloride 1 mg per mL, 473 mL substitute: Oral solution containing hydromorphone hydrochloride 1 mg per mL, 1 mL

[2]        Schedule 4, entry for Calcipotriol with betamethasone

omit:

Calcipotriol with betamethasone

Gel containing calcipotriol 50 micrograms with betamethasone
500 micrograms (as dipropionate) per g, 60 g

[3]        Schedule 4, after entry for Nicorandil in the form Tablets 20 mg, 60

insert:

Nirmatrelvir and ritonavir

Pack containing 4 tablets nirmatrelvir 150 mg and 2 tablets ritonavir 100 mg, 5